We demonstrated that DLL4-targeted nanoparticles with a small fraction of anti-DLL4 dose (0.75-1 mg/Kg of DLL4 antibody) compared with anti-DLL4 monotherapy provides an effective therapeutic option for patients whose genetic variants promote upregulated DLL4 expression in the tumor vasculature and nanoparticle mediated blockade of DLL4 may not cause dose-related liver and vascular toxicities. The gene discussed is DLL4; the disease is neoplasm.